PIRS (pieris.com) Bozor qiymatining balans qiymatiga nisbati

Pieris Pharmaceuticals Inc (PIRS) kompaniyasining rasmiy ramzlari

Pieris Pharmaceuticals (PIRS) sanoat gigantlari bilan strategik ittifoqlar orqali respirator va onkologik dori vositalari ishlab chiqarishni kengaytirmoqda. Balans hisoboti bilan nisbatan bozor kapitalizatsiyasi dinamikasi ushbu trayektoriya tasdiqlaydi, bunda 8.79 joriy metrika darajasi sifatida xizmat qilmoqda. Kompaniya maqsadli terapiya uchun mo‘ljallangan innovatsion antikalin proteinlari bilan qadrlanadi. Hozirgi vaqtda biznes onkologiya sohasiga kengayish uchun yangi hamkorlarni aniqlashga e'tibor qaratgan holda o'z portfelini qayta tuzmoqda.

PIRS Pieris Pharma: Balans qiymatiga nisbatan bozor qiymati 04.07.2022 - 28.10.2026 oraligʻida

Pieris Pharmaceuticals Inc (PIRS) moliyaviy va bozor koʻrsatkichlari kesimi

- narx va narxlar bo'yicha konsensus prognoz:
Narx grafigi Pieris Pharmaceuticals|PIRS - Tahlilchilar median maqsadi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor qiymati Pieris|PIRS - Biznesning to‘liq qiymati
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya hisobiga balans qiymati Pieris Pharmaceuticals|PIRS - Kompaniyaning buxgalteriya qiymati|Bozor kapitallashuvining balans qiymatiga nisbati pieris.com|PIRS - Kompaniyaning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Qarzning xususiy kapitalga nisbati Pieris Pharmaceuticals|PIRS - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Qisqa muddatli qarzning o'z kapitaliga nisbati Pieris|PIRS - Kompaniyaning umumiy qarzi|Balans kapitallashuviga qarzlar Pieris|PIRS - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli majburiyatlari Pieris Pharmaceuticals
Kompaniyaning dastlabki tahlili:Pieris Pharmaceuticals - PIRS
Pieris original mahsuloti

Pieris Pharmaceuticals kompaniyasining Anticalin asosidagi dori vositalarini ishlab chiqishi sof aktiv qiymatining tebranishlariga bevosita ta'sir ko'rsatadi. Ushbu ko'rsatkich biznesning joriy bozor qiymatini uning haqiqiy balans kapitali bilan solishtiradi. U aksiyalar qiymatining haddan tashqari yuqori yoki past baholanganlik darajasini o'lchash orqali fundamental xavfsizlik zaxirasini belgilaydi. Pozitsiyaga kirishda risklarni minimallashtirish uchun investorlarga ushbu vektorni kuzatib borish juda muhimdir. Narxning buki qiymatiga nisbati (price-to-book ratio) tahlili optimal kirish nuqtalarini aniqlashga yordam beradi.

Asosiy raqobatchilar

Haleon plc - Bozor qiymatining balans qiymatiga nisbati|KVUE (kenvue.com) - Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati Verona Pharma VRNA|Sof aktivlarga nisbatan bozor kapitallashuvi Jyong Biotech Limited|Ligand Pharma (LGND) - Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati Amneal Corp (AMRX)|Bozor kapitallashuvining balans qiymatiga nisbati PRGO (Perrigo Company plc)|alvotech.com - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati Liquidia (LQDA)|GLPG: Balans qiymatiga nisbatan bozor qiymati|ANIP (ANI Pharma) - Bozor qiymatining balans qiymatiga nisbati|Afrezza (MNKD) - Kapitallashuvning sof aktivlarga nisbati|AMPH (Amphastar Pharmaceuticals) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati pacira.com (PCRX)|ARS Pharmaceuticals, Inc. (SPRY) - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati TBPH (Theravance Biopharma Inc)|AQST: Bozor qiymatining balans qiymatiga nisbati|SCPH - Bozor qiymatining balans qiymatiga koeffitsiyenti|Kapitallashuvning sof aktivlarga nisbati Tectonic TECX|TNXP - Bozor kapitallashuvining balans qiymatiga multiplikatori|Bozor kapitallashuvining balans qiymatiga nisbati sxtchina.com SXTC|Eupraxia Pharmaceuticals Inc. (EPRX) - Balans qiymatiga nisbatan bozor qiymati|Bozor kapitallashuvining balans qiymatiga nisbati BHST (BioHarvest)|Bozor qiymatining balans qiymatiga koeffitsiyenti EXOZ|Oramed Pharmaceuticals (ORMP) - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati ENTX (enterabio.com)|MindWalk Holdings Inc. (HYFT) - Bozor qiymatining balans qiymatiga nisbati|Sof aktivlarga nisbatan bozor kapitallashuvi ABVC BioPharma Inc. ABVC|Bozor kapitallashuvining balans qiymatiga nisbati CPIX (Cumberland Pharma)|QNTM - Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati FGEN|TELO (telomirpharma.com) - Bozor qiymatining balans qiymatiga koeffitsiyenti|RANI - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati Synergy CHC Corporation|RLYB (Rallybio Corporation) - Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi LEXX (lexariabioscience.com)|Bozor qiymatining balans qiymatiga nisbati PULM|PTHL - Balans qiymatiga nisbatan bozor kapitallashuvi|Kapitallashuvning sof aktivlarga nisbati Aptorum (APM)|LYRA: Balans qiymatiga nisbatan bozor qiymati|Bozor qiymatining balans qiymatiga nisbati Impact BioMedical (IBO)|TNF Pharmaceuticals, Inc. (TNFA) - Sof aktivlarga nisbatan bozor kapitallashuvi|YCBD - Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati painreform.com|Bozor kapitallashuvining balans qiymatiga nisbati CYTO|Bozor kapitallashuvining balans qiymatiga nisbati LIPO (Lipella Pharmaceuticals Inc)|Bozor qiymatining balans qiymatiga nisbati Optinose|Procaps Group Corp - Balans qiymatiga nisbatan bozor qiymati|PTPI: Bozor qiymatining balans qiymatiga nisbati|QLI - Kapitallashuvning sof aktivlarga nisbati|SLRN: Bozor kapitallashuvining balans qiymatiga nisbati|TFF Pharmaceuticals Inc. (TFFP) - Bozor kapitallashuvining balans qiymatiga nisbati